Epitalon is pitched online as the telomere peptide that could slow aging, but a new 2026 review says the evidence tells a different story. Human data are limited to small biomarker studies and one older retinitis pigmentosa trial, with no adequately powered randomized trial showing efficacy. Dosing, pharmacokinetics, and long-term safety remain unvalidated, and questions about cancer risk, immunogenicity, product quality, and FDA scrutiny are still open. Here's what the science supports, what it doesn't, and who should steer clear.
This page is available in